CVRx
CVRX
93 hedge funds and large institutions have $192M invested in CVRx in 2024 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 12 closing their positions.
496% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $173K
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
53% more capital invested
Capital invested by funds: $125M → $192M (+$67M)
8% more funds holding
Funds holding: 86 → 93 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.91% less ownership
Funds ownership: 65.38% → 62.47% (-2.9%)
13% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 30
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$7.68M |
| 2 |
SAM
Silvercrest Asset Management
New York
|
+$4.59M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.94M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$2.35M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.05M |
Top Sellers
CVRX Hedge Fund Activity: Q4 2024 in Review
93 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in CVRx (CVRX) for Q4 2024, worth a combined $192M — up 53% from $125M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CVRX positions and 12 closed out — a net gain of 7 holders — while 26 added to existing stakes and 30 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $7.68M. The largest seller was NEA Management Company, cutting an estimated $4.25M.
- 93 institutional investors held CVRx (CVRX) as of Q4 2024, up from 86 in Q3 2024.
- Funds reported $192M of CVRx stock for Q4 2024, up 53% quarter-over-quarter.
- 19 funds opened new CVRx positions in Q4 2024 and 12 closed out, a net change of +7 holders.
- The largest CVRx buyer in Q4 2024 was JP Morgan Chase, an estimated $7.68M added.
- The largest CVRx seller in Q4 2024 was NEA Management Company, an estimated $4.25M sold.
Based on aggregated 13F filings for Q4 2024.